Pull to refresh
Logo
Broad Institute of MIT and Harvard

Broad Institute of MIT and Harvard

Research institute

Appears in 6 stories · Last updated Nov 2, 2026

Stories

Huntington's cortical neuron loss linked to large somatic DNA repeat expansions

New Capabilities

Produced companion paper and 2025 striatum study

Huntington's disease has long been framed as a protein problem: mutant huntingtin clumps inside neurons and kills them. A new Cell study maps 428,173 cortical cells and finds that the neurons most likely to die carry extreme somatic expansions of the CAG repeat, beyond 450 repeats.

Updated Nov 2

Abbott launches next-generation Oncodetect test to track cancer recurrence

New Capabilities

Developed and licensed MAESTRO technology

Cancer patients often finish treatment not knowing whether it worked. Abbott's new Oncodetect test, launched October 26, tries to answer that question sooner. The blood test tracks up to 5,000 mutations unique to each patient's tumor and can detect cancer DNA at concentrations below one part per million.

Updated Oct 26

Mitochondria atlas across tree of life reveals parasite drug targets

New Capabilities

Co-led the MitoCarta Tree of Life project

Scientists have mapped the full set of mitochondrial proteins in six organisms: five parasites and one plant. Combined with existing human and yeast inventories, the catalog covers 8,619 proteins in 3,199 families, including 33 families found in parasites but not in people.

Updated Oct 21

Google DeepMind releases AlphaGenome Atlas, a predictive map of all 9 billion human DNA variants

New Capabilities

As of September 2026: Collaborator on rare disease applications of the Atlas

Google DeepMind released AlphaGenome Atlas on Tuesday, a free online database that predicts the effects of all 9 billion possible single-letter changes to human DNA. The 1-petabyte resource, built on the AlphaGenome AI model, is the most complete catalogue of human genetic variation ever built.

Updated Sep 9

New CRISPR-engineered cancer models decode how tumors outsmart targeted therapies

New Capabilities

As of May 2026: Received 2026 AACR Team Science Award for DepMap; poster presented at AACR 2026; awaiting DepMap portal data release for resistance models

Every year, hundreds of thousands of lung cancer patients start treatment with osimertinib, the leading targeted therapy for tumors driven by mutations in the EGFR gene. Most will respond, but nearly all will eventually stop responding as their cancers evolve resistance through a dozen different molecular escape routes. Until now, researchers had to work with messy lab models that made it hard to pin down which genetic change caused which failure.

Updated May 31

Machine learning reveals bacteria carry far more antiviral defenses than scientists assumed

New Capabilities

As of May 2026: Home institution of the DefensePredictor team

Every major tool in genetic engineering — from the enzymes that cut DNA in the 1970s to CRISPR gene editing — started as a defense weapon bacteria use against viruses. Two teams revealed bacteria carry three times more weapons than anyone realized, identifying millions of antiviral proteins from tens of thousands of genomes using machine-learning models that flag a new defense system in five minutes.

Updated May 31